Literature DB >> 16204369

Effect of cyclic adenosine 3',5'-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas.

G Mantovani1, S Bondioni, S Ferrero, B Gamba, E Ferrante, E Peverelli, S Corbetta, M Locatelli, P Rampini, P Beck-Peccoz, A Spada, A G Lania.   

Abstract

CONTEXT: Alterations in cAMP signaling have been identified as a cause of endocrine neoplasia. In particular, activating mutations of the G(s)alpha gene and protein kinase A (PKA) overactivity due to low expression of PKA regulatory subunit 1A (R1A) have been implicated in somatotroph proliferation.
OBJECTIVE: The objective of this study was to evaluate the effects of cAMP-PKA cascade activation in nonfunctioning pituitary adenomas (NFPA). DESIGN AND METHODS: By immunohistochemistry, R1A, R2A, and R2B expression was evaluated in cells obtained from eight surgically removed NFPA positive for gonadotropins. Cyclin D1 expression and ERK1/2 activity were analyzed under basal conditions and after cAMP-PKA cascade activation.
RESULTS: Immunohistochemistry studies demonstrated a low R1/R2 ratio in all NFPA. Additional unbalance of R1/R2 ratio by 8-chloroadenosine cAMP (8-Cl-cAMP) and direct adenylyl cyclase stimulation by forskolin did not increase cyclin D1 expression or ERK1/2 activity in five NFPA (group 1), but even caused 74 +/- 15% and 85 +/- 13% inhibitions of cyclin D1 and ERK1/2 activity, respectively, in the remaining NFPA (group 2). Moreover, in group 2, PKA blockade by the specific inhibitor PKI increased cyclin D1 expression (96 +/- 25% over basal) and ERK1/2 activity (116 +/- 28% over basal).
CONCLUSIONS: These data show that in contrast with what was previously observed in transformed somatotrophs, activation of the cAMP-PKA pathway did not generate proliferative signals in tumoral cells of the gonadotroph lineage, and in a subset of tumors even exerted a tonic inhibitory effect, thus confirming a different role for the cAMP-mediated pathway in promoting proliferation in the pituitary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204369     DOI: 10.1210/jc.2005-0977

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

2.  mTOR links incretin signaling to HIF induction in pancreatic beta cells.

Authors:  Sam Van de Velde; Meghan F Hogan; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

3.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

4.  Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.

Authors:  Kevin M Riggle; Kimberly J Riehle; Heidi L Kenerson; Rigney Turnham; Miwako K Homma; Machiko Kazami; Bret Samelson; Renay Bauer; G Stanley McKnight; John D Scott; Raymond S Yeung
Journal:  Pediatr Res       Date:  2016-03-08       Impact factor: 3.756

5.  Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis.

Authors:  Zhirong Yin; Lisa Williams-Simons; A F Parlow; Sylvia Asa; Lawrence S Kirschner
Journal:  Mol Endocrinol       Date:  2007-11-01

6.  Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma.

Authors:  Kimberly J Riehle; Heidi L Kenerson; Kevin M Riggle; Rigney Turnham; Kevin Sullivan; Renay Bauer; John D Scott; Raymond S Yeung
Journal:  Oncotarget       Date:  2019-08-20

7.  Protein kinase a in cancer.

Authors:  Antonio Caretta; Carla Mucignat-Caretta
Journal:  Cancers (Basel)       Date:  2011-02-28       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.